Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Two-period Cross-over Study of the Effect of Ensifentrine on Sputum Markers of Inflammation in Patients With COPD

NCT05270525 is registered in ClinicalTrials.gov with Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA as lead sponsor.

NCT NCT05270525
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05270525 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Two-period Cross-over Study of the Effect of Ensifentrine on Sputum Markers of Inflammation in Patients With COPD
Lead sponsor
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 27, 2022
Completion date
March 1, 2027
Enrollment
56 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

copd